ISSN 0975-3583

Journal of Cardiovascular Disease Research

    Role of propranolol in the management strategies of infantile hemangioma from a tertiary care hospital

    Dr. Venkataramana G, Dr. Malle Nagaveni, Dr. Bhanu Prakash Goud, Dr. Srinivas
    JCDR. 2023: 746-752


    To study the impact of propranolol in the management of Infantile Hemangiomas. Methods: This prospective study was conducted in Department of Pediatrics, Navodaya Medical College Hospital and Research Centre, Mantralayam Road, Raichur, Karnataka, India over a period April 2021 to March 2022. All children with hemangiomas attending in hospital outpatient department during the study period. Results: The mean duration of propranolol therapy for superficial and deep hemangiomas was 8.96 months and 8.8 months respectively. For the hemangiomas in the head region, the mean duration of propranolol therapy was 9.72months and for the hemangiomas in the trunk and the extremities it was 8.6 and 10.5 months respectively. Conclusion: All children tolerated propranolol well without significant side effects. No one had required interruption or withdrawal of propranolol therapy for side effects.


    » PDF

    Volume & Issue

    Volume 14 Issue 2